The Economic Case for Expanding Vaccination Coverage of Children by Till Bärnighausen et al.
 
 
 PROGRAM ON THE GLOBAL 
  DEMOGRAPHY OF AGING 
   
 
 





The Economic Case for Expanding  





Till Bärnighausen, David E. Bloom, David Canning, Abigail Friedman, Orin 

















The views expressed in this paper are those of the author(s) and not necessarily those of the Harvard 
Initiative for Global Health. The Program on the Global Demography of Aging receives funding from the 
National Institute on Aging, Grant No. 1 P30 AG024409-06. 
  
The Economic Case for Expanding  















Till Bärnighausen, University of KwaZulu-Natal 
  
David E. Bloom, Harvard School of Public Health 
 
David Canning, Harvard School of Public Health 
 
Abigail Friedman, Harvard School of Public Health 
 
Orin Levine, Johns Hopkins Bloomberg School of Public Health 
 
Jennifer O'Brien, Harvard School of Public Health 
 
Lois Privor-Dumm, Johns Hopkins Bloomberg School of Public Health 
 











   1 
 
*We thank Christian Bjørnskov for his helpful suggestions and Larry Rosenberg and Marija 
Ozolins for useful comments and research assistance.  We gratefully acknowledge funding 
support from GAVI’s PneumoADIP at The Johns Hopkins Bloomberg School of Public Health 
through the grant “Benefit-cost analyses for vaccination against pneumococcous, rotavirus, 
Haemophilus influenzae type B, and other vaccine-preventable diseases”. Abstract 
 
While childhood vaccination programs, such as WHO’s Expanded Program on 
Immunization, have had a dramatic impact on child morbidity and mortality 
worldwide, lack of coverage with several existing vaccines is responsible for large 
numbers of child deaths each year, mostly in developing countries.  According to 
WHO estimates, increased coverage of three vaccines alone – pneumococcal 
conjugate vaccine (PCV), rotavirus vaccine (Rota), and Haemophilus influenzae 
type b (Hib) vaccine – could have prevented one and a half million deaths in 
children under five years in 2002.  In deciding whether to implement interventions 
to expand vaccination coverage policy makers often consider economic 
evaluations.  Past evaluations, however, have usually ignored both important 
vaccination benefits and potentially large cost reductions in vaccination delivery.  
We demonstrate for the example of benefit-cost analysis (BCA) of the Hib 
vaccination that past studies have mostly taken narrow evaluation perspectives, 
focusing on health gains, health care cost savings, and reductions in the time 
costs that parents incur when taking care of sick children, while ignoring other 
benefits, in particular, outcome-related productivity gains  (Hib vaccination can 
prevent permanent mental and physical disabilities) behavior-related productivity 
gains (reductions in child mortality due to Hib can trigger changes in fertility which 
in turn may stimulate economic growth) and community externalities (Hib 
vaccination can prevent the development of antibiotic resistance and reduce the 
risk of Hib infections in unvaccinated persons).  We further show that the costs of 
Hib vaccine delivery can be reduced if the monovalent Hib vaccine is replaced by 
combination vaccines.  Such cost reductions have usually been ignored in CBA 
of Hib.  Our analysis thus suggests that past BCAs are likely to have substantially 
underestimated the value of Hib vaccination, even though most have found it to 
be cost-beneficial.  Unless future BCAs of childhood vaccinations take full 
account of benefits and costs, policy makers may lack sufficient information to 
make the right decisions on vaccination interventions. 
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 Recent history of childhood vaccination 
 
Childhood vaccination programs have had a dramatic impact on child morbidity 
and mortality worldwide.  A universal effort to extend vaccination coverage to all 
children began in 1974, when the World Health Organization (WHO) founded the 
Expanded Program on Immunization (EPI).  This initiative helped countries 
establish the infrastructure needed to deliver a standard vaccination package 
(original EPI in Table 1), which in 1974 included the vaccine against diphtheria-
tetanus-pertussis (DTP), measles-containing vaccine (MCV), polio vaccine (Pol), 
and Bacillus Calmette-Guérin (BCG) vaccine.  Over time, additional vaccines 
have been added to national EPI packages in some countries (later-stage EPI in 
Table 1), including those against Haemophilus influenzae type b (Hib) infection, 
yellow fever, and hepatitis B (Halsey & Galazka, 1985). 
 
Despite the longstanding availability of EPI vaccines and national health policies 
aiming at universal or near universal coverage (WHO, 1974), actual coverage is 
widely incomplete.  For instance, Lim et al. (2008) estimated that, in 2006, 26% 
of children younger than one year of age worldwide had not received the third 
dose of the DTP vaccination series (DTP3) (Lim, Stein, Charrow, & Murray, 
2008).  DTP3 is commonly used as an indicator to assess the performance of 
national vaccination systems because it captures a system’s capacity to 
repeatedly vaccinate the same individual and to record vaccination doses and 
because DTP is included in most routine vaccination schedules worldwide.  The 
lack of DTP3 coverage thus suggests that vaccination systems are not reaching 
millions of children (Lim et al., 2008). 
 
Incomplete vaccination coverage, in turn, leads to large numbers of avoidable 
child deaths.  Currently, the three vaccine-preventable diseases responsible for 
the highest mortality burdens in children are pneumococcal disease, rotavirus 
infection, and Hib infection, which in 2002 were responsible, respectively, for 
716,000, 402,000, and 386,000 deaths in children under five years of age (WHO, 
2003).  Those children who do not die from vaccine-preventable diseases may 
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 suffer debilitating sequelae.  For example, Hib infection and pneumococcal 
disease can cause bacterial meningitis, which may lead to severe neurological 
conditions such as deafness, blindness, or intellectual impairment.  Rotavirus 
infection can lead to malnutrition in early childhood, potentially resulting in 
stunted height.  Vaccination against these diseases, therefore, can avert both 
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 Table 1: Vaccination data summary 
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Number of deaths worldwide in 





72%  81%  5,000 diphtheria (2002) (WHO, 
2009a) 
294,000 pertussis, (2002) (WHO, 
2009b) 
18,000 non-neonatal tetanus 
(2002) (WHO, 2009b) 
Measles-containing 
vaccine (MCV) 
71%  82%  217,000 (2006) (WHO, 2008b) 















Guérin vaccine (BCG) 
79% 89%  
Haemophilus influenzae 
type b vaccine (Hib3) 
8%  26%  386,000 (2002) (WHO, 2009b) 
Yellow fever vaccine 
(YF) 

















Hepatitis B vaccine 
(HepB3) 






























  716,000 (2002) (WHO, 2009b) 
*In this column, we show the name of each vaccine and the abbreviation used to denote the last 
dose of the vaccine in the full vaccination series (excluding booster doses), i.e. DTP3 = third dose 
of diphtheria-tetanus-pertussis vaccine, MCV = first dose of measles-containing vaccine, Polio3 = 
third dose of polio vaccine, BCG = first dose of Bacillus Calmette-Guérin vaccine, Hib3 = third 
dose of Haemophilus influenzae type b vaccine, YF = first dose of yellow fever vaccine, HepB3 = 
third dose of hepatitis B vaccine, Rota2 = second dose of rotavirus vaccine (Rotarix®), Rota3 = 
third dose of rotavirus vaccine (RotaTeq®), PCV 3 = third dose of pneumococcal conjugate 
vaccine. 
†Vaccination coverage is the average coverage with the last dose of the full vaccination series 
across the WHO Member States.  It is expressed as a percentage of the target population.  While 
the “target population varies depending on the countries’ policies”, in “most instances the target 
population is the number of children surviving their first year of life” (WHO, 2008b). 
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 In deciding whether to finance a health care intervention, decision makers 
commonly consider not only the effects of the intervention but also the costs.  
Cost-effectiveness analyses (CEA) and benefit-cost analyses (BCAs) are the 
most common approaches to systematically compare the costs and effects of 
health care interventions.  CEA evaluates the health effectiveness of an 
intervention (measured in a common unit, e.g., life-years or quality-adjusted life-
years) relative to the costs (measured in monetary units), while BCA compares 
monetary measures of intervention benefits to costs.  Below, we argue that 
economic evaluations of vaccination have traditionally adopted a narrow 
perspective, considering only some categories of vaccination effects, while 
disregarding others, and have failed to take into account changes in vaccine 
costs that can be achieved by combining several vaccines into a single delivery 
system.   
 
Such a narrow perspective can lead to an underestimation of the benefits of a 
vaccination and to an overestimation of its costs, resulting in wrong decisions on 
vaccination roll-out.  A broad perspective in BCA, CEA, or other types of 
economic evaluation of vaccinations should thus replace the narrow perspective.  
We have chosen the Hib vaccine as an example to make this case.  While the 
Hib vaccination has been introduced into national schedules in most countries 
worldwide, with a global coverage of merely 26%, it has the lowest coverage of 
those vaccinations that are commonly included in EPI (Table 1) (WHO, 2008b).  
It is also among the vaccinations that could prevent the largest number of deaths 
in children under five years of age.  Unlike the two other vaccines that could, on 
their own, prevent even larger numbers of deaths in children in this age group – 
the vaccine against pneumococcal disease (which could prevent 716,000 deaths 
annually) or rotavirus infection (which could prevent 402,000 deaths annually) – 
Hib vaccine can be combined with the DTP vaccine and delivered as a 
multivalent formulation in a single injection (DTP-Hib).  Vaccination with DTP-Hib 
could prevent 703,000 deaths annually, i.e., more deaths than the rotavirus 
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The Haemophilus influenzae type b vaccine 
 
Infection with Hib can give rise to different diseases and disease sequelae.  Non-
invasive Hib infection occurs when the bacteria enter a non-sterile liquid, e.g., the 
lungs or the nasal passages.  Such infections can cause pneumonia, particularly 
in infants and children.  Invasive disease involves penetration by the bacteria of a 
sterile liquid such as the blood or cerebrospinal fluid, which can lead to 
bacteremia or acute bacterial meningitis, respectively.  The highest rates of Hib-
related morbidity and mortality are associated with invasive Hib disease.  In 
1985, a polysaccharide vaccine against Hib was licensed in the United States.  
However, the vaccine displayed limited immunogenicity among children under 
two years of age and was not effective in reducing the incidence of infection.  It 
was later removed from the market.  In 1987, the United States licensed a 
protein-conjugated Hib vaccine with high efficacy among children under two 
years of age (WHO, 2008a).  One-hundred and sixty countries either introduced 
the Hib vaccine by 2009 or are expected to introduce it by 2010 (Figure 1) 
(Anonymous, 2009b).  
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Source: (Anonymous, 2009b) 
 
 
Many studies have demonstrated the success of the Hib conjugate vaccine in 
reducing child morbidity and mortality.  For instance, following routine use of the 
Hib conjugate vaccine in the US since 1990, the national incidence of invasive 
Hib disease decreased from pre-vaccination levels of 41 per 100,000 per year (in 
1987) to approximately 1 case per 100,000 children per year (in 1997) 
(Anonymous, 1998).  A 2006 study in Kenya showed that the vaccination 
reduced the incidence of Hib disease by 88% within three years and prevented 
approximately 3,370 Kenyan children from being hospitalized in 2005 (Cowgill, 
Ndiritu, Nyiro, Slack, Chiphatsi, Ismail et al., 2006).  A 2007 study in Bangladesh 
found that routine Hib vaccination of infants could prevent over one third of Hib 
pneumonia cases and approximately 90% of meningitis cases (Baqui, El Arifeen, 
Saha, Persson, Zaman, Gessner et al., 2007).  A 2008 study in Uganda 
estimated that within four years of introduction of the Hib vaccine into the national 
vaccination program, the incidence of Hib meningitis declined by 85%.  By the 
fifth year after introduction the number of cases had fallen to nearly zero (Lee, 
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 Lewis, Makumbi, Kekitiinwa, Ediamu, Bazibu et al., 2008).  These studies 
suggest that the Hib vaccine is highly effective at reducing Hib-related morbidity 
and mortality in a variety of settings. 
 
 
Benefit-cost analysis of Hib vaccination 
 
We performed a comprehensive literature review of BCAs of Hib vaccination in 
order to assess which benefits and costs have been taken into account in past 
studies.  We chose to review the literature on BCA rather than CEA because our 
argument that economic evaluations of vaccination have traditionally accounted 
for too narrow a set of benefits focuses on both health and non-health benefits.  
Non-health benefits of vaccinations can be easily incorporated in BCA since all 
benefits are measured in monetary units.  CEA of vaccinations, on the other 
hand, measure the health benefits (or effects) in natural units, so that non-health 
benefits cannot be added to the benefits side of the analysis.  Thus, BCA is the 
more natural evaluation framework to demonstrate one of our main points.  
Nevertheless, it is theoretically possible to account for those non-health benefits 
that have often been neglected in economic evaluations of vaccinations in a CEA 
by expressing them as cost savings and incorporating these savings into the cost 
side of the analysis.   
 
We searched medical, economic, and general literature databases (EconLit 
(Anonymous, 2009a), PubMed (Anonymous, 2009d), Science Citation Index 
Expanded (Anonymous, 2009e), and JSTOR (Anonymous, 2009c)) in order to 
identify BCAs that evaluate Hib vaccination at the national or subnational level.  
In our search, we found 62 distinct economic evaluation studies of Hib 
vaccination published from January 1985 through March 2009.  After excluding 
all studies that did not use BCA as an evaluation approach or reported only 
regional results, 11 studies remained in our final selection for review (see below).  
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 Rethinking the benefits of vaccination 
 
BCAs of vaccination programs have usually focused on gains in health, health 
care costs, and the time costs of parents taking care of their sick children.  
However, a new understanding of the linkages between health and wealth, and of 
vaccine-related externalities, suggests that this understanding of vaccine-related 
benefits is incomplete and neglects a number of long-term individual- and 
population-level gains.  Approaching BCA of vaccination from a broad 
perspective that accounts for these additional gains invites a new and more 
comprehensive conceptualization of the benefits of vaccination.  Table 2 outlines 
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Definition Hib-specific  examples 
Health gains  Reduction in mortality 
through vaccination
2 
Hundreds of thousands of children die each 
year from Hib disease (WHO, 2009b). 
Health care 
cost savings 




Hib diseases lead to substantial health care 
costs (Akumu, 2007; Gessner, 2008; F. Zhou, 
Jeanne Santoli, Mark L. Messonnier, Hussain R. 
Yusuf, Abigail Shefer, Susan Y. Chu, Lance 











Savings of parents’ 
productive time because 
vaccination avoids the 
need for taking care of a 
sick child 
Parental care of children suffering from Hib 
disease can contribute to the overall cost of the 








physical strength, and 
school attainment 
Hib meningitis is relatively common (WHO, 
2008a), and Hib meningitis “leaves 15 to 35% of 
survivors with permanent disabilities such as 
mental retardation or deafness”, severely 





Benefits accruing because 
vaccination improves child 
health and survival and 
thereby changes 
household behavior 
Hundreds of thousands of children die each 






   
Community 
externalities 
Benefits accruing because 
vaccination improves 
outcomes in unvaccinated 
community members 
Hib infections are treated with antibiotics, 
leading to the development of resistance 
(Elbasha, 2003). 
Hib vaccinations can protect unvaccinated 
individuals through herd effects (Stephens, 
2008). 
Source: (Bärnighausen et al., 2008) 
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2 The denominator of the cost-effectiveness ratio in CEA is either a measure of mortality (e.g. 
number of life-years saved), morbidity (e.g. cases of meningitis averted) or mortality and 
morbidity (e.g. number of disability-adjusted life-years saved).  Thus, for CEA the benefits 
considered in the narrow-perspective category “health gains” should be defined as “reduction in 
mortality or morbidity through vaccination” (Bärnighausen, Bloom, Canning, & O'Brien, 2008).  
Outcome-related productivity gains due to reductions in morbidity could be incorporated 
separately in the denominator of the cost-effectiveness ratio, but are commonly ignored.  In 
contrast, in BCAs “health gains” in terms of the value of saved life-years are commonly 
considered (for example, in 9 out of 11 studies in Table 3), while morbidity reductions are rarely 
included in the valuation (for example, in only 1 out of the 11 studies in Table 3).  If morbidity 
reductions are included in BCA, they are usually valued as outcome-related productivity gains.  
Since the focus of this paper is on BCA, we assign mortality reductions, but not morbidity 
reductions, to the category “health gains”.  
 
Categories of vaccination benefits that are usually ignored in economic 
evaluation studies of vaccinations, such as Hib vaccination, include outcome-
related productivity gains, behavior-related productivity gains, and community 
externalities (see Table 2 for definitions of these types of benefits).  Below, we 
describe examples in these three benefit categories for Hib vaccination.   
 
Outcome-related productivity gains 
Childhood vaccinations may result in outcome-related productivity gains 
(Bärnighausen et al., 2008) because they protect children’s physical health and 
ability to achieve their full cognitive potential.  Children who are physically and 
cognitively healthy are more likely to attend school and to attain high education 
levels; adults who are physically healthy and well educated can work more and 
more productively (see Bloom and Canning (2009) for a review of the literature 
on the relationships between health, cognitive development, education, and labor 
productivity (D. E. Bloom & Canning, 2009)).  Hib vaccination can avert long-term 
neurological sequelae of Hib infection, such as blindness, deafness, mental 
retardation, epilepsy, and paralysis (WHO, 2005).  Such sequelae can severely 
affect a child’s ability to attend school and to learn.  For example, a longitudinal 
study in Australia comparing outcomes in adolescents who survived a bout of 
bacterial meningitis, such as Hib meningitis, to outcomes in controls who did not 
suffer from meningitis revealed “substantial excess risk of intellectual, cognitive, 
and auditory impairment” and “[c]ontinuing developmental problems of higher 
order language, organisation, problem solving, and central auditory function” in 
the meningitis survivors, resulting in lower educational achievement and higher 
risk of behavior disorders (Grimwood, Anderson, Anderson, Tan, & Nolan, 2000).  
As cognitive ability and educational achievements are related to labor productivity 
and income (Colclough, Kingdon, & Patrinos, 2008; Psacharopoulos & Patrinos, 
2004), these findings suggest that the roll-out of a vaccination that protects 
against common causes of meningitis, such as Hib, can increase a country’s 
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 economic growth – a benefit that can potentially be measured and should be 
taken into account in BCA of vaccinations against Hib and other infections. 
Behavior-related productivity gains 
Broad-perspective economic analyses also account for gains in productivity that 
come about when vaccination effects change behavior.  For instance, in areas 
with high child mortality rates, couples may choose to have more children in 
order to ensure the survival of a sufficient number of children who can work to 
support the family.  As Hib vaccination can reduce child mortality, mothers of 
vaccinated children can achieve their target family size through fewer births.  
Having fewer children allows parents to invest more resources in each child, 
improving its nutrition, health, and educational attainment.  These improvements, 
in turn, will increase a child’s labor productivity as an adult. 
 
At the population level, reductions in fertility rates will decrease the number of 
youth dependents relative to the size of the adult labor force, because fewer 
children are born and more women can participate in the labor market.  A larger 
share of working-age individuals supporting a smaller number of children can 
lead to increased savings.  The additional savings can be used to invest in 
physical and human capital, stimulating economic growth.  Research suggests 
that this phenomenon of rising shares of working-age people leading to increases 
in the rate of economic growth (the so-called demographic dividend (D. Bloom, 
Canning, & Sevilla, 2003)) contributed substantially to economic development in 
the Republic of Ireland (D. Bloom & Canning, 2003) and several East Asian 




In addition to outcome- and behavior-related productivity gains, community 
externalities are also typically overlooked in economic analyses of vaccination.  
In the case of Hib vaccination, these include herd effects and reductions in 
antibiotic resistance.  Herd effects refer to the reduction in an unvaccinated 
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 person’s risk of contracting a disease due to the vaccination of another person.  
For instance, a study of Navajo Indians in the US found that children under two 
years of age who lived in communities where 20-39% and 40-59% had received 
at least one dose of Hib vaccine had, respectively, a 56.5% and 73.2% lower risk 
of invasive Hib disease than their peers who lived in communities with 0-19% Hib 
vaccination coverage, independent of their own Hib vaccination status (Moulton, 
Chung, Croll, Reid, Weatherholtz, & Santosham, 2000).  Herd effects will be 
especially significant in countries where large proportions of the unvaccinated 
population are at increased risk of contracting a vaccine-preventable infection 
and developing severe forms of the disease, for instance, because of old age or 
HIV infection.  
 
Vaccinations can lead to another type of community externality by avoiding the 
development of antibiotic resistance.  Many bacterial infections, including Hib 
infection, are treated using antibiotics.  The probability of antibiotic resistance 
increases with the number of patients treated with an antibiotic.  In the case of 
Hib, infections with strains that are resistant to first-line antibiotics can be treated 
with second- and third-line antibiotics.  However, these later-stage drugs may not 
be available in some settings and are far more costly than their first-line 
counterparts (Saha, Darmstadt, Baqui, Islam, Qazi, Islam et al., 2008).  
According to a recent study by Saha et al. (Saha et al., 2008), the proportion of 
cases of infection with Hib that are resistant to the first-line antibiotics ampicillin 
and chloramphenicol has risen to roughly 50%.  Hib vaccination can prevent 
disease and thus obviate the need for antibiotic use, reducing the prevalence of 
antibiotic-resistant strains.  This benefit is shared by communities, governments, 
and medical institutions, which might otherwise have to shoulder the morbidity 
burden, costs, and work load associated with treating antibiotic-resistant strains.  
 
Broadening the perspective on benefits in benefit-cost analysis of Hib vaccination 
Of the 11 studies we identified in our review as reporting results from BCA of Hib 
vaccination (Table 3), nine found a benefit-cost ratio (BCR) greater than one (or 
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 positive net benefits).  Two studies, one in South Korea (Shin, Shin, & Ki, 2008) 
and the other one in Chile (Lagos, Levine, Avendano, Horwitz, & Levine, 1998), 
found BCRs that were smaller than one.  Overall, BCRs ranged from 0.12 to 
8.39.  These results seem to suggest that in some countries introducing the Hib 
vaccination into national vaccination schedules may not be cost-beneficial.  Such 
a conclusion, however, may be wrong because none of the 11 reviewed studies 
included all broad-perspective benefits in the evaluation.  In fact, while all 11 
studies included the benefit category health care cost savings, nine the category 
health gains, and eight the category care-related productivity gains, only one 
study (Shin et al., 2008) took a broad-perspective benefit category into account in 
the analysis (outcome-related productivity gains).  Thus, BCA that account for 
broad-perspective benefits in addition to those included under a narrow 
perspective (Table 2) would be expected to find BCR that are (even) more 
favorable than those shown in Table 3.  For example, Levine et al. (1998) 
demonstrated in an analysis of infant vaccination with Hib in developing countries 
that the estimated health-related benefits of the vaccination increase when herd 
effects are taken into account (by 38%, measured in DALYS) (Levine, Schwartz, 
Pierce, & Kane, 1998).   
 
Studies by Bloom, Canning, and Weston also used BCA to account for a wide 
array of vaccine-mediated benefits (D. Bloom, Canning, & Weston, 2005).  Their 
investigation of the impact of the Global Alliance for Vaccines and Immunization 
(GAVI) program to expand coverage of new and underused vaccines, including 
Hib vaccine, used life tables to measure the contributions to countries’ gross 
national products of children who, by virtue of vaccination, survive and enter the 
labor force as healthy workers.  They estimated that the vaccination program 
would have a return on investment (ROI) of 18% by 2020.
3  In another analysis, 
n examined the ROI of a vaccination program (that  Bloom, Canning, and Westo
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3 Education – considered by many to be one of the most important means of economic 
development – has ROIs of similar magnitude (ranging from 19% for primary education to 11% 
for tertiary education) (Psacharopoulos & Patrinos, 2004).    16 
 
did not include Hib vaccine) using cognitive testing data from the Philippines’ 
Cebu Longitudinal Health and Nutritional Survey.  Translating cognitive gains 
among vaccinated children into income values as adults, the ROI was 21%.  
These studies suggest that a proper accounting of the impact of vaccination 
requires an understanding of the broad scope of vaccine-mediated benefits.  
Ignoring the broad-perspective benefits of vaccination may lead to wrong 




















 Table 3: Cost-benefit analyses of Hib vaccination 
 
 


















Valency of vaccine 
formulation 
(Asensi, Otero, Perez-Tamarit, 
Miranda, Pico, & Nieto, 1995) 
Spain
††    2.4 - 5.1*  100%  1, 2  Invasive 
disease  
3 monovalent 
(Garpenholt, Silfverdal, & Levin, 
1998) 
Sweden  Net benefits per 
child: 160 SEK 
99%  1, 2, 3  All  3  monovalent 
(Ginsberg et al., 1993)  Israel  1.45  88%  1, 2, 3  All  4  monovalent 
(Jimenez, Guallar-Castillon, Rubio 
Terres, & Guallar, 1999) 
Spain  1.49  90%  1, 2, 3  Invasive 
disease  
4 monovalent 
(Lagos et al., 1998)  Chile  0.12-1.10  100%  2  All  3  monovalent 
(Levine, Ortiz, Contreras, Lagos, 
Vial, Misraji et al., 1993) 
Chile
†††   1.66  87%  2  Invasive 
disease 
3 monovalent 
(Limcangco, Armour, Salole, & 
Taylor, 2001) 
Philippines  8.39*  85%  1, 2, 3  Meningitis  3  monovalent 
(Shin et al., 2008)  Korea  0.77   90%   1, 2, 3, 4  All  3   monovalent 
(Trollfors, 1994)  Sweden  1.6   100%  1, 2, 3  Meningitis and 
acute epiglottis 
3 monovalent 
(Pokorn, Kopac, Neubauer, & 
Cizman, 2001) 
Slovenia  1.38   95%  1, 2, 3  Invasive 
disease  
3 monovalent 
(F. Zhou, Bisgard, Yusuf, Deuson, 
Bath, & Murphy, 2002) 
USA  5.4  93%  1, 2, 3  Invasive 
disease 
3, 4  monovalent and 
multivalent 
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1 = health gains, 2 = health care cost savings, 3 = care-related productivity gains, 4 = outcome-related productivity gains (see Table 2 for 
definitions of these types of benefits).  BCR = Benefit-cost ratio. 
*BCR was calculated using data provided in the publication.  
†When several BCRs were provided in the publication for different sets of benefits, 
we selected the BCR estimated for the largest set of benefits.  If the BCR could not be calculated using data shown in the publication, we selected 
the net benefits as a summary measure of the BCA result.  
††Analysis was conducted at a subnational level (Valencia).  
†††Analysis was conducted 
at a subnational level (Santiago).  SEK = Swedish Kronor. Rethinking the costs of Hib vaccination  
 
While narrow-perspective BCA of vaccination programs may underestimate the 
benefits of Hib vaccination, they may also overstate its costs by failing to account 
for savings that can occur when vaccines are combined and delivered in a single 
vial.  Many of the vaccination costs commonly included in BCA – the costs of the 
vaccine serum, syringes, cold storage, and health worker time of administering 
the vaccination – can be reduced when, instead of delivering a vaccine in single, 
monovalent form, it is added to an existing vaccine formulation in a multivalent 
solution.  The resulting reduction in cost can be particularly large if the 
vaccination antigen is added to a vial that contains DTP, which typically has the 
broadest coverage within the existing vaccination network.  
 
For instance, the Hib vaccine can not only be delivered in monovalent form but 
also in combination with the trivalent DTP or the tetravalent DTP-HepB vaccine 
(i.e. as tetravalent DTP-Hib or pentavalent DTP-Hep-Hib vaccine, respectively).  
The pentavalent DTP-HepB-Hib vaccine is already being used in several 
countries and recommended for use by UNICEF, GAVI, and WHO (UNICEF, 
2008; UNICEF & WHO, 2009).  With one exception, all BCAs of the Hib vaccine 
identified in our review estimate the value of adding the monovalent vaccine to 
current national vaccination schedules (Table 3).  However, the costs of adding 
the Hib vaccine in multivalent formulations to vaccines that are already delivered 
in the schedules will be lower than those of adding the monovalent formulation.  
Using the cheapest price estimates of DTP in the UNICEF/WHO 2009 
Immunization Summary (UNICEF & WHO, 2009) and the cheapest price 
estimates of Hib, DTP-Hib, and DTP-HepB-Hib in the UNICEF Vaccine 
Projections for 2009 (UNICEF, 2009), an added dose of monovalent Hib will cost 
US$ 3.4, while the addition of Hib in the tetravalent formulation DTP-Hib will cost 
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 US$3.1, and the addition of Hib in the pentavalent DTP-Hep-Hib will cost US$ 
2.8.
4   
Comparing the costs of phasing in a monovalent Hib vaccine with those of 
replacing DTP with a tetravalent or a pentavalent vaccine further requires 
consideration of the amount of hazardous waste generated, the volume of 
storage required, and differences in the time required to administer the vaccines.  
Disposing of biohazardous waste is very expensive, often requiring costly 
incinerators, which can be particularly burdensome for developing countries.  
However, the costs of improperly disposing of the syringes and vials used in 
vaccinations – which include the costs of infections, environmental degradation, 
and social opposition to vaccination – may be even larger.
5  Adding the Hib 
vaccination through use of the tetravalent or the pentavalent vaccination implies 
that no syringes would need to be used in addition to those already in use for the 
DTP or the DTP-HepB three-shot vaccination series (Agrawal, Singh, & Mahesh, 
2004).  
 
Nearly all vaccines must be transported and stored in temperature-controlled 
conditions known as the cold-chain storage network.  This network constitutes a 
major implementation cost for all countries.  Cold storage costs increase with 
vaccination volume.  When using the lowest volume-per-dose estimate of Hib, 
DTP, DTP-Hib, and DTP-HepB-Hib listed in the WHO Vaccine Volume Calculator 
(WHO, 2009c), the addition of one dose of monovalent Hib requires storage room 
3), while the addition of Hib in the tetravalent DTP- for 3.3 cubic centimeters (cm
                                                        
4 The price estimates are weighted average prices across countries eligible for funding through 
GAVI (UNICEF, 2009). 
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5 For instance, WHO estimates for 2000 identify contaminated syringes and needles as the cause 
of 32% of all new hepatitis B infections, 40% of all new hepatitis C infections, and 5% of all new 
HIV infections, resulting in significant morbidity, mortality, and monetary costs for individuals and 
society. This is a particular issue in developing countries as few have established systems for 
managing sharps waste.  In remote and rural areas of developing countries, the combination of 
poor road conditions and personnel reluctant to transport the unwieldy and hazardous waste 
contributes to inappropriate and unsafe disposal, often through shallow burial or open burning. 
Urban areas face similar problems because primary health clinics rarely have access to hospitals’ 
incinerators and thus dispose of sharps in public waste sites—where rag pickers may come 
across them—or through open burning, which is often toxic (Program for Appropriate Technology 
in Health (PATH), 2006). Hib requires no additional storage room and the addition of Hib in DTP-HepB-Hib 
requires storage room for 0.6 cm
3, i.e. the increase in cold chain costs will be 
substantially higher for monovalent Hib than for the addition of Hib in its 
multivalent formulations. 
 
Finally, it is immediately apparent that health worker time to administer 
vaccinations will be shorter if fewer injections are required.  Adding Hib in a 
multivalent formulation will thus be less time-consuming than adding it in its 
monovalent form. 
 
A study of Ethiopia’s national vaccination services shows the size of the savings 
that can be achieved by combining vaccines into a single vial.  The study found 
that cold chain storage costs alone accounted for over 75% of all system costs 
per fully vaccinated child, with a cost of US$0.03 per additional cm
3 of cold 
storage (Griffiths, Korczak, Ayalew, & Yigzaw, 2009).  As the added volume 
required for storing the tetravalent DTP-Hib or the pentavalent DTP-HepB-Hib 
vaccines is less than that required for the monovalent Hib vaccine, using the 
pentavalent vaccine would be expected to significantly reduce system costs 
associated with cold chain storage relative to the use of the monovalent vaccine. 
 
Broadening the perspective on costs in benefit-cost analysis of Hib vaccination 
None of the studies in our review of BCA of Hib vaccination estimated the BCR 
when exclusively using pentavalent Hib formulations (Table 3);  only one (Shin et 
al., 2008) of the 11 studies indentified considered cost reductions due to 
replacing the monovalent Hib vaccine with a combination vaccine.  At baseline, 
the study estimated the BCR of Hib vaccination using the actual distribution of 
monovalent and multivalent Hib vaccines in the USA in 2000 (yielding a BCR of 
5.4).  In sensitivity analysis the study then recalculated the BCR assuming that all 
Hib vaccinations were performed either with the monovalent formulation (yielding 
a BCR of 5.0) or with a HepB-Hib combination vaccine (BCR of 7.5), 
demonstrating the increase in the estimate of vaccination value if multivalent 
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 formulations are used in evaluation as opposed to monovalent vaccines.  It is 
likely that all studies listed in Table 3 would have found substantially higher BCRs 
had they evaluated the tetravalent DTP-Hib or the pentavalent DTP-HepB-Hib 




Policy makers often consider economic evaluations in deciding whether to 
introduce a vaccine into national vaccination schedules or to implement 
campaigns to improve vaccination coverage (Fuguitt & Wilcox, 1999).  Past 
economic evaluations of vaccinations, however, have usually ignored both 
important benefits and potentially large cost reductions and may thus have 
substantially underestimated the value of vaccinations.  We demonstrate, for the 
example of the Hib vaccine, that BCAs have taken narrow evaluation 
perspectives, focusing on health gains, health care cost savings, and care-
related productivity gains, while ignoring other benefits, in particular, outcome-
related productivity gains (Hib vaccine can prevent permanent mental and 
physical disabilities), behavior-related productivity gains (reductions in child 
mortality due to Hib can trigger changes in fertility which in turn may stimulate 
economic growth), and community externalities (Hib vaccination can prevent the 
development of antibiotic resistance and reduce the risk of Hib infection in 
unvaccinated persons).   
 
Similarly, economic evaluations of vaccinations have usually ignored savings that 
can be achieved if economies of scope in vaccination delivery are fully exploited.  
We show for the example of the Hib vaccine that substantial cost reductions are 
likely to occur if a monovalent Hib formulation is replaced by a combination 
vaccine in the evaluation, because adding the Hib vaccine to a vaccination 
schedule in a multivalent form reduces serum cost, waste, storage volume, and 
health worker time.  Theoretically, combination vaccines may have a few 
disadvantages.  For instance, if only combination vaccines are available in a 
country, some children may unnecessarily forgo the opportunity to receive some 
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 vaccinations because they have a medical contraindication against one specific 
vaccine included in the combination.  This potential problem, however, may not 
affect a large number of children and can be avoided by using combination 
vaccines in routine situations but offering children with vaccine-specific 
contraindications those vaccines they can safely receive in monovalent forms.  
Our analysis thus suggests that past BCAs of Hib vaccination have 
underestimated the value of the vaccination, even though most have found it to 
be cost-beneficial.  One hundred sixty countries either introduced the Hib vaccine 
by 2009 or are expected to introduce it by 2010.  Nevertheless, Hib vaccination 
coverage remains low (26% in 2007).  Our results should encourage researchers 
to conduct BCA of Hib vaccination that take into account broad sets of benefits 
and cost.  According to our findings, the results of such research are likely to 
strengthen the case for interventions to increase Hib vaccination coverage. 
 
It is important to keep in mind that the different benefits and costs included in 
broad-perspective economic evaluations of vaccinations accrue at different times 
relative to the date of vaccination.  For instance, the timing of health gains will 
depend on the disease avoided by the vaccination – some diseases, such as 
measles, will mostly affect children, while others, such as hepatitis B, may afflict 
both children and adults and thus lead to health gains throughout the life course.  
Outcome-related productivity gains will usually start accruing only once the 
vaccinated children have become adults and enter the labor market.  Behavior-
related productivity gains may materialize only after a long lag times because 
changes in child health and survival may first need to be observed in children 
already born before they can change future fertility decisions.  Cost reductions 
due to changes in vaccine formulation, on the other hand, will be realized 
immediately at the time of the vaccination.  Because the broad-perspective 
evaluation expands the sets of benefits and costs included in the analysis, the 
relative timing of benefit and cost realization will more complex than in narrow-
perspective studies.  Broader evaluation perspectives may thus require more 
complex evaluation methodologies.  The increased demand on the skill of the 
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 evaluator, however, should not distract from the fact that broad-perspective 
evaluations will improve the validity of evaluation results and should thus be 
routinely undertaken.  
 
Understanding the complex links between vaccination programs, health, 
education, and labor productivity has implications for all vaccines, not just the Hib 
vaccine.  In particular, the broad-perspective approach to economic evaluation 
should be applied to new vaccines, such as PCV and Rota, that are more 
expensive than the vaccines currently included in most EPI.  A broadening of 
evaluation perspective that is not considered above relates to the possibility that 
the children who would be vaccinated if vaccination coverage were to be 
expanded in a country stand to benefit more from vaccination than children who 
were vaccinated in the past.  A number of studies suggest that children who 
reside farther away from clinics, who come from lower economic status 
households or larger families, or whose mothers have fewer years of education 
or less knowledge about health and health care, are less likely to receive 
vaccinations (Bondy, Thind, Koval, & Speechley, 2009; Cui & Gofin, 2007; 
Ndirangu, Bärnighausen, Tanser, Khin, & Newell, 2009; Ndiritu, Cowgill, Ismail, 
Chiphatsi, Kamau, Fegan et al., 2006; Waters, Dougherty, Tegang, Tran, 
Wiysonge, Long et al., 2004).  Children with these characteristics are more likely 
to suffer if they contract a vaccine-preventable disease than children who live in 
more privileged circumstances, because they will be less likely to have access to 
health care and to support systems that can reduce the effect of disease 
sequelae on their lives.  At the same time, it is likely that the marginal costs of 
extending vaccination coverage to additional children are increasing.  Past 
economic evaluations have usually assumed that the vaccination benefits and 
costs observed in vaccinated children are valid for those children who are 
currently unvaccinated.  Future BCAs of Hib and other vaccinations should take 
into account that both the costs and benefits of a vaccination may change as 
coverage increases, possibly changing overall estimates of the vaccination BCR. 
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 As vaccinations could save the lives of large numbers of children – PCV and 
Rota together have the potential to save the lives of more than one million 
children under the age of five – expanding vaccination coverage can clearly 
contribute to the progress towards the fourth Millennium Development Goal 
(MDG) of reducing child mortality.  Broad-perspective economic evaluation can 
draw attention to the non-health benefits of vaccination, including effects on 
educational attainment (which are relevant for the second MDG of achieving 
universal primary education) and labor productivity (which is relevant for the first 
MDG of eradicating extreme poverty and hunger).  Only when all benefits of 
vaccinations for health, education, and the economy of a country are considered 
simultaneously with the cost of vaccine delivery will policy makers have sufficient 
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